Table of Contents

1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Overview

• 1.1 Product Overview and Scope of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
• 1.2 Classification of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Type
  • 1.2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Type: 2015 VS 2019 VS 2025
  • 1.2.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Type in 2019
  • 1.2.3 PCR
  • 1.2.4 In-situ Hybridization
  • 1.2.5 Immunohistochemistry
  • 1.2.6 Sequencing
  • 1.2.7 Others
• 1.3 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by Application
  • 1.3.1 Overview: Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Application: 2015 VS 2019 VS 2025
  • 1.3.2 Oncology
  • 1.3.3 Neurological Disorders
  • 1.3.4 Cardiovascular Disease
  • 1.3.5 Immunological Disorders
  • 1.3.6 Others
• 1.4 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by Regions
  • 1.4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions: 2015 VS 2019 VS 2025
  • 1.4.2 Global Market Size of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) (2015-2025)
  • 1.4.3 North America (USA, Canada and Mexico) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
  • 1.4.4 Europe (Germany, France, UK, Russia and Italy) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
  • 1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
  • 1.4.6 South America (Brazil, Argentina, Colombia) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
  • 1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)

2 Company Profiles

• 2.1 Qiagen NV
  • 2.1.1 Qiagen NV Details
  • 2.1.2 Qiagen NV Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.1.3 Qiagen NV SWOT Analysis
  • 2.1.4 Qiagen NV Product and Services
  • 2.1.5 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
• 2.2 Pfizer
  • 2.2.1 Pfizer Details
  • 2.2.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.2.3 Pfizer SWOT Analysis
  • 2.2.4 Pfizer Product and Services
  • 2.2.5 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
• 2.3 F Hoffman La Roche
  • 2.3.1 F Hoffman La Roche Details
  • 2.3.2 F Hoffman La Roche Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.3.3 F Hoffman La Roche SWOT Analysis
  • 2.3.4 F Hoffman La Roche Product and Services
  • 2.3.5 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
• 2.4 GE Healthcare
  • 2.4.1 GE Healthcare Details
  • 2.4.2 GE Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.4.3 GE Healthcare SWOT Analysis
  • 2.4.4 GE Healthcare Product and Services
  • 2.4.5 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
• 2.5 Leica Biosystems Nussloch GmBH
  • 2.5.1 Leica Biosystems Nussloch GmBH Details
  • 2.5.2 Leica Biosystems Nussloch GmBH Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.5.3 Leica Biosystems Nussloch GmBH SWOT Analysis
  • 2.5.4 Leica Biosystems Nussloch GmBH Product and Services
  • 2.5.5 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
• 2.6 Agilent Technologies
  • 2.6.1 Agilent Technologies Details
  • 2.6.2 Agilent Technologies Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.6.3 Agilent Technologies SWOT Analysis
  • 2.6.4 Agilent Technologies Product and Services
  • 2.6.5 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
• 2.7 Thermo Fisher Scientific Inc.
  • 2.7.1 Thermo Fisher Scientific Inc. Details
  • 2.7.2 Thermo Fisher Scientific Inc. Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.7.3 Thermo Fisher Scientific Inc. SWOT Analysis
  • 2.7.4 Thermo Fisher Scientific Inc. Product and Services
  • 2.7.5 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
• 2.8 Foundation Medicine
  • 2.8.1 Foundation Medicine Details
  • 2.8.2 Foundation Medicine Major Business and Total Revenue (Financial Highlights) Analysis
  • 2.8.3 Foundation Medicine SWOT Analysis
  • 2.8.4 Foundation Medicine Product and Services
  • 2.8.5 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)

3 Market Competition, by Players

• 3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Share by Players (2015-2020)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players Market Share
  • 3.2.2 Top 10 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players Market Share
• 3.3 Market Competition Trend

4 Market Size by Regions

• 4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Market Share by Regions
• 4.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 4.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 4.4 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 4.5 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 4.6 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)

5 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries

• 5.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
• 5.2 USA Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 5.3 Canada Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 5.4 Mexico Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)

6 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries

• 6.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
• 6.2 Germany Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 6.3 UK Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 6.4 France Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 6.5 Russia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 6.6 Italy Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)

7 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries

• 7.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
• 7.2 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 7.3 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 7.4 Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 7.5 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 7.6 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)

8 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries

• 8.1 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
• 8.2 Brazil Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 8.3 Argentina Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)

9 Middle East & Africa Revenue Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Countries

• 9.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
• 9.2 Saudi Arabia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 9.3 UAE Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 9.4 Egypt Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
• 9.5 South Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)

10 Market Size Segment by Type

• 10.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Market Share by Type (2015-2020)
• 10.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Type (2019-2024)
• 10.3 PCR Revenue Growth Rate (2015-2025)
• 10.4 In-situ Hybridization Revenue Growth Rate (2015-2025)
• 10.5 Immunohistochemistry Revenue Growth Rate (2015-2025)
• 10.6 Sequencing Revenue Growth Rate (2015-2025)
• 10.7 Others Revenue Growth Rate (2015-2025)

11 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Segment by Application

• 11.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Application (2015-2020)
• 11.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Application (2019-2024)
• 11.3 Oncology Revenue Growth (2015-2020)
• 11.4 Neurological Disorders Revenue Growth (2015-2020)
• 11.5 Cardiovascular Disease Revenue Growth (2015-2020)
• 11.6 Immunological Disorders Revenue Growth (2015-2020)
• 11.7 Others Revenue Growth (2015-2020)

12 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast (2021-2025)

• 12.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast (2021-2025)
• 12.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Regions (2021-2025)
• 12.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
• 12.4 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
• 12.5 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
• 12.6 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
• 12.7 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Data Source
• 14.3 Disclaimer

Market Overview
The global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.6% in the forecast period of 2020 to 2025 and will expected to reach USD 6615.9 million by 2025, from USD 5125 million in 2019.

The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market has been segmented into:
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others

By Application, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) has been segmented into:
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market presented in the report. This section sheds light on the sales growth of different regional and country-level Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market.

The report offers in-depth assessment of the growth and other aspects of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share Analysis
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) sales, revenue and market share for each player covered in this report.

The major players covered in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) are:
Qiagen NV
Pfizer
F Hoffman La Roche
GE Healthcare
Leica Biosystems Nussloch GmBH
Agilent Technologies
Thermo Fisher Scientific Inc.
Foundation Medicine